Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Non-Current Assets (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Non-Current Assets data on record, last reported at $9.0 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 113.56% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $29.6 million, up 34.33%, while the annual FY2025 figure was $9.0 million, 113.56% up from the prior year.
  • Non-Current Assets reached $9.0 million in Q4 2025 per AMLX's latest filing, down from $9.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $52.8 million in Q4 2023 and bottomed at $663000.0 in Q4 2021.
  • Average Non-Current Assets over 5 years is $12.9 million, with a median of $9.0 million recorded in 2025.
  • Peak YoY movement for Non-Current Assets: surged 1305.73% in 2022, then plummeted 92.04% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $663000.0 in 2021, then soared by 1305.73% to $9.3 million in 2022, then skyrocketed by 466.39% to $52.8 million in 2023, then tumbled by 92.04% to $4.2 million in 2024, then skyrocketed by 113.56% to $9.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $9.0 million in Q4 2025, $9.4 million in Q3 2025, and $7.7 million in Q2 2025.